Celcuity (CELC) Projected to Post Earnings on Monday

Celcuity (NASDAQ:CELC) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Celcuity to post earnings of ($1.06) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

Celcuity Trading Down 6.2%

Shares of CELC stock opened at $106.04 on Monday. The company has a market cap of $4.91 billion, a PE ratio of -28.89 and a beta of 0.38. Celcuity has a 1 year low of $7.57 and a 1 year high of $120.32. The stock’s 50 day simple moving average is $109.40 and its two-hundred day simple moving average is $89.43. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wells Fargo & Company initiated coverage on Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $122.00 price target on shares of Celcuity in a research report on Tuesday, March 17th. Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group increased their target price on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and a consensus price target of $108.63.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the sale, the director directly owned 90,000 shares in the company, valued at approximately $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 15.78% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Several hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the period. US Bancorp DE boosted its stake in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Celcuity during the fourth quarter valued at $42,000. Tower Research Capital LLC TRC grew its holdings in shares of Celcuity by 211.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock worth $74,000 after purchasing an additional 3,766 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Celcuity in the fourth quarter worth about $101,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.